Clinical Trial Update: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 3F8/GM-CSF immunotherapy with 13-cis-retinoic acid for primary refractory neuroblastoma in bone marrow has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 13-cis-retinoic acid (13-cis-retinoic acid)
• 3F8
• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED | Results posted: 2019-08-13